Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: Sequence and structural comparison

Drug Resistance Updates

Volumn 12, Issue 1-2, 2009, Pages 28-41

  Volpato, Jordan P ^a   Pelletier, Joelle N ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antifolate; Dihydrofolate reductase; Drug resistance; Homology; Mutations

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DIHYDROFOLIC ACID; FOLIC ACID ANTAGONIST; METHOTREXATE; PYRIMETHAMINE; TRIMETHOPRIM; TRIMETREXATE;

ARTICLE; BACTERIAL INFECTION; BACTERIUM; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POINT MUTATION; PRIORITY JOURNAL; PROTOZOON; SEQUENCE ANALYSIS; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, NEOPLASM; FOLIC ACID ANTAGONISTS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTOZOAN PROTEINS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 62949106183     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2009.02.001     Document Type: Article

References (129)

1. Alam M.T., Bora H., Bharti P.K., Saifi M.A., Das M.K., Dev V., Kumar A., Singh N., Dash A.P., Das B., Wajihullah, and Sharma Y.D. Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. Antimicrob. Agents Chemother. 51 (2007) 857-863
2. Allay J.A., Persons D.A., Galipeau J., Riberdy J.M., Ashmun R.A., Blakley R.L., and Sorrentino B.P. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat. Med. 4 (1998) 1136-1143
3. Arrebola R., Olmo A., Reche P., Garvey E.P., Santi D.V., Ruiz-Perez L.M., and Gonzalez-Pacanowska D. Isolation and characterization of a mutant dihydrofolate reductase-thymidylate synthase from methotrexate-resistant Leishmania cells. J. Biol. Chem. 269 (1994) 10590-10596
4. Baccanari D.P., Daluge S., and King R.W. Inhibition of dihydrofolate reductase: effect of reduced nicotinamide adenine dinucleotide phosphate on the selectivity and affinity of diaminobenzylpyrimidines. Biochemistry 21 (1982) 5068-5075
5. Baccanari D.P., Stone D., and Kuyper L. Effect of a single amino acid substitution on Escherichia coli dihydrofolate reductase catalysis and ligand binding. J. Biol. Chem. 256 (1981) 1738-1747
6. Banerjee D., and Bertino J.R. Myeloprotection with drug-resistance genes. Lancet Oncol. 3 (2002) 154-158
7. Banerjee D., Schweitzer B.I., Volkenandt M., Li M.X., Waltham M., Mineishi S., Zhao S.C., and Bertino J.R. Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance. Gene 139 (1994) 269-274
8. Banerjee D., Zhao S.C., Tong Y., Steinherz J., Gritsman K., and Bertino J.R. Transfection of a nonactive site mutant murine DHFR cDNA (the tryptophan 15 mutant) into Chinese hamster ovary and mouse marrow progenitor cells imparts MTX resistance in vitro. Cancer Gene Ther. 1 (1994) 181-184
9. Bell D.J., Nyirongo S.K., Mukaka M., Zijlstra E.E., Plowe C.V., Molyneux M.E., Ward S.A., and Winstanley P.A. Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS ONE 3 (2008) e1578
10. Belzile J.P., Karatzas A., Shiu H.Y., Letourneau S., Palerme J.S., and Cournoyer D. Increased resistance to nitrogen mustards and antifolates following in vitro selection of murine fibroblasts and primary hematopoietic cells transduced with a bicistronic retroviral vector expressing the rat glutathione S-transferase A3 and a mutant dihydrofolate reductase. Cancer Gene Ther. 10 (2003) 637-646
11. Capiaux G.M., Budak-Alpdogan T., Alpdogan O., Bornmann W., Takebe N., Banerjee D., Maley F., and Bertino J.R. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther. 11 (2004) 767-773
12. Capiaux G.M., Budak-Alpdogan T., Takebe N., Mayer-Kuckuk P., Banerjee D., Maley F., and Bertino J.R. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Hum. Gene Ther. 14 (2003) 435-446
13. Champness J.N., Achari A., Ballantine S.P., Bryant P.K., Delves C.J., and Stammers D.K. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 Å resolution. Structure 2 (1994) 915-924
14. Chen G.X., Mueller C., Wendlinger M., and Zolg J.W. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum. Mol. Pharmacol. 31 (1987) 430-437
15. Cheng, K.K.-F. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer. Eur. J. Cancer Care, in press.
16. Chongsuphajaisiddhi T., and Sabchareon A. Sulfadoxine-pyrimethamine resistant falciparum malaria in Thai children. Southeast Asian J. Trop. Med. Public Health 12 (1981) 418-421
17. Chu E., and Allegra C.J. Antifolates. Cancer Chemotherapy and Biotherapy (1996), Lippincott-Raven, Philadelphia, PA
18. Chu E., Takimoto C.H., Voeller D., Grem J.L., and Allegra C.J. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 32 (1993) 4756-4760
19. Chunduru S.K., Cody V., Luft J.R., Pangborn W., Appleman J.R., and Blakley R.L. Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. J. Biol. Chem. 269 (1994) 9547-9555
20. Chusacultanachai S., Thiensathit P., Tarnchompoo B., Sirawaraporn W., and Yuthavong Y. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol. Biochem. Parasitol. 120 (2002) 61-72
21. Coderre J.A., Beverley S.M., Schimke R.T., and Santi D.V. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 2132-2136
22. Cody V., Galitsky N., Luft J.R., Pangborn W., Rosowsky A., and Blakley R.L. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry 36 (1997) 13897-13903
23. Cody V., Galitsky N., Rak D., Luft J.R., Pangborn W., and Queener S.F. Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP+. Biochemistry 38 (1999) 4303-4312
24. Cody V., Luft J.R., and Pangborn W. Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr. D Biol. Crystallogr. 61 (2005) 147-155
25. Cowman A.F., Morry M.J., Biggs B.A., Cross G.A., and Foote S.J. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 9109-9113
26. Dale G.E., Broger C., D'Arcy A., Hartman P.G., DeHoogt R., Jolidon S., Kompis I., Labhardt A.M., Langen H., Locher H., Page M.G., Stuber D., Then R.L., Wipf B., and Oefner C. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J. Mol. Biol. 266 (1997) 23-30
27. Das J.R., Fryar E.B., Epie N.N., Southerland W.M., and Bowen D. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res. 26 (2006) 1877-1883
28. Davies II J.F., Delcamp T.J., Prendergast N.J., Ashford V.A., Freisheim J.H., and Kraut J. Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry 29 (1990) 9467-9479
29. Daw N.C., Billups C.A., Rodriguez-Galindo C., McCarville M.B., Rao B.N., Cain A.M., Jenkins J.J., Neel M.D., and Meyer W.H. Metastatic osteosarcoma. Cancer 106 (2006) 403-412
30. de Groot R., Chaffin D.O., Kuehn M., and Smith A.L. Trimethoprim resistance in Haemophilus influenzae is due to altered dihydrofolate reductase(s). Biochem. J. 274 Pt 3 (1991) 657-662
31. de Pecoulas P.E., Tahar R., Ouatas T., Mazabraud A., and Basco L.K. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol. Biochem. Parasitol. 92 (1998) 265-273
32. Delfino R.T., Santos-Filho O.A., and Figueroa-Villar J.D. Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR. Biophys. Chem. 98 (2002) 287-300
33. Dicker A.P., Waltham M.C., Volkenandt M., Schweitzer B.I., Otter G.M., Schmid F.A., Sirotnak F.M., and Bertino J.R. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11797-11801
34. Dolnick B.J., Berenson R.J., Bertino J.R., Kaufman R.J., Nunberg J.H., and Schimke R.T. Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells. J. Cell Biol. 83 (1979) 394-402
35. Dolznig H., Kolbus A., Leberbauer C., Schmidt U., Deiner E.M., Mullner E.W., and Beug H. Expansion and differentiation of immature mouse and human hematopoietic progenitors. Methods Mol. Med. 105 (2005) 323-344
36. Ellenberger T.E., and Beverley S.M. Multiple drug resistance and conservative amplification of the H region in Leishmania major. J. Biol. Chem. 264 (1989) 15094-15103
37. Ercikan-Abali E.A., Mineishi S., Tong Y., Nakahara S., Waltham M.C., Banerjee D., Chen W., Sadelain M., and Bertino J.R. Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 56 (1996) 4142-4145
38. Ercikan-Abali E.A., Waltham M.C., Dicker A.P., Schweitzer B.I., Gritsman H., Banerjee D., and Bertino J.R. Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties. Mol. Pharmacol. 49 (1996) 430-437
39. Farber S., Diamond L.K., Mercer R.D., Sylvester R.F., and Wolff V.A. N. Engl. J. Med. 238 (1948) 787-793
40. Ferone R., Burchall J.J., and Hitchings G.H. Plasmodium berghei dihydrofolate reductase. Isolation, properties, and inhibition by antifolates. Mol. Pharmacol. 5 (1969) 49-59
41. Flasshove M., Banerjee D., Mineishi S., Li M.X., Bertino J.R., and Moore M.A. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85 (1995) 566-574
42. Flensburg J., and Skold O. Massive overproduction of dihydrofolate reductase in bacteria as a response to the use of trimethoprim. Eur. J. Biochem. 162 (1987) 473-476
43. Foote S.J., Galatis D., and Cowman A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3014-3017
44. Fossati E., Volpato J.P., Poulin L., Guerrero V., Dugas D.A., and Pelletier J.N. 2-tier bacterial and in vitro selection of active and methotrexate-resistant variants of human dihydrofolate reductase. J. Biomol. Screen. 13 (2008) 504-514
45. Gatlin J., Douglas J., Evans J.T., Collins R.H., Wendel G.D., and Garcia J.V. In vitro selection of lentivirus vector-transduced human CD34+ cells. Hum. Gene Ther. 11 (2000) 1949-1957
46. Gilbert I.H. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim. Biophys. Acta 1587 (2002) 249-257
47. Goker E., Lin J.T., Trippett T., Elisseyeff Y., Tong W.P., Niedzwiecki D., Tan C., Steinherz P., Schweitzer B.I., and Bertino J.R. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7 (1993) 1000-1004
48. Goker E., Waltham M., Kheradpour A., Trippett T., Mazumdar M., Elisseyeff Y., Schnieders B., Steinherz P., Tan C., Berman E., et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86 (1995) 677-684
49. Goldie J.H., Krystal G., Hartley D., Gudauskas G., and Dedhar S. A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells. Eur. J. Cancer 16 (1980) 1539-1546
50. Goldman I.D. The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts. Mol. Pharmacol. 10 (1974) 257-274
51. Hankins E.G., Warhurst D.C., and Sibley C.H. Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. Mol. Biochem. Parasitol. 117 (2001) 91-102
52. Happi C.T., Gbotosho G.O., Folarin O.A., Akinboye D.O., Yusuf B.O., Ebong O.O., Sowunmi A., Kyle D.E., Milhous W., Wirth D.F., and Oduola A.M. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 95 (2005) 183-193
53. Hashkes P.J., and Laxer R.M. Update on the medical treatment of juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 8 (2006) 450-458
54. Hastings M.D., and Sibley C.H. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13137-13141
55. Havenga M.J., Werner A.B., Valerio D., and van Es H.H. Methotrexate selectable retroviral vectors for Gaucher disease. Gene Ther. 5 (1998) 1379-1388
56. Hawser S., Lociuro S., and Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71 (2006) 941-948
57. Hekmat-Nejad M., and Rathod P.K. Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp. Parasitol. 87 (1997) 222-228
58. Hitchings G.H. Species differences among dihydrofolate reductases as a basis for chemotherapy. Postgrad. Med. J. 45 Suppl. (1969) 7-10
59. Hock R.A., and Miller A.D. Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature 320 (1986) 275-277
60. Huovinen P., Sundstrom L., Swedberg G., and Skold O. Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39 (1995) 279-289
61. Imwong M., Pukrittakayamee S., Looareesuwan S., Pasvol G., Poirreiz J., White N.J., and Snounou G. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob. Agents Chemother. 45 (2001) 3122-3127
62. Imwong M., Pukrittayakamee S., Renia L., Letourneur F., Charlieu J.P., Leartsakulpanich U., Looareesuwan S., White N.J., and Snounou G. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob. Agents Chemother. 47 (2003) 1514-1521
63. Jones G., Crotty M., and Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst. Rev. (2000) (CD000212)
64. Knighton D.R., Kan C.C., Howland E., Janson C.A., Hostomska Z., Welsh K.M., and Matthews D.A. Structure of and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat. Struct. Biol. 1 (1994) 186-194
65. Kongsaeree P., Khongsuk P., Leartsakulpanich U., Chitnumsub P., Tarnchompoo B., Walkinshaw M.D., and Yuthavong Y. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 13046-13051
66. Kovalevskaya N.V., Smurnyy Y.D., Polshakov V.I., Birdsall B., Bradbury A.F., Frenkiel T., and Feeney J. Solution structure of human dihydrofolate reductase in its complex with trimethoprim and NADPH. J. Biomol. NMR 33 (2005) 69-72
67. Kramer B.A., Lemckert F.A., Alexander I.E., Gunning P.W., and McCowage G.B. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow. J. Gene Med. 8 (2006) 1071-1085
68. Leartsakulpanich U., Imwong M., Pukrittayakamee S., White N.J., Snounou G., Sirawaraporn W., and Yuthavong Y. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol. Biochem. Parasitol. 119 (2002) 63-73
69. Lewis W.S., Cody V., Galitsky N., Luft J.R., Pangborn W., Chunduru S.K., Spencer H.T., Appleman J.R., and Blakley R.L. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J. Biol. Chem. 270 (1995) 5057-5064
70. Li R., Sirawaraporn R., Chitnumsub P., Sirawaraporn W., Wooden J., Athappilly F., Turley S., and Hol W.G. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295 (2000) 307-323
71. Lin J.T., Tong W.P., Trippett T.M., Niedzwiecki D., Tao Y., Tan C., Steinherz P., Schweitzer B.I., and Bertino J.R. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk. Res. 15 (1991) 1191-1196
72. Lorico A., Bratbak D., Meyer J., Kunke D., Krauss S., Plott W.E., Solodushko V., Baum C., Fodstad O., and Rappa G. Gamma-glutamylcysteine synthetase and L-buthionine-(S, R)-sulfoximine: a new selection strategy for gene-transduced neural and hematopoietic stem/progenitor cells. Hum. Gene Ther. 16 (2005) 711-724
73. Lynch G., Magill G.B., Sordillo P., and Golbey R.B. Combination chemotherapy of advanced sarcomas in adults with "CYOMAD" (S7). Cancer 50 (1982) 1724-1727
74. Ma L., and Kovacs J.A. Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob. Agents Chemother. 44 (2000) 3092-3096
75. Margosiak S.A., Appleman J.R., Santi D.V., and Blakley R.L. Dihydrofolate reductase from the pathogenic fungus Pneumocystis carinii: catalytic properties and interaction with antifolates. Arch. Biochem. Biophys. 305 (1993) 499-508
76. Maskell J.P., Sefton A.M., and Hall L.M. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45 (2001) 1104-1108
77. Matthews D.A., Bolin J.T., Burridge J.M., Filman D.J., Volz K.W., Kaufman B.T., Beddell C.R., Champness J.N., Stammers D.K., and Kraut J. Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J. Biol. Chem. 260 (1985) 381-391
78. McGready R., Stepniewska K., Seaton E., Cho T., Cho D., Ginsberg A., Edstein M.D., Ashley E., Looareesuwan S., White N.J., and Nosten F. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur. J. Clin. Pharmacol. 59 (2003) 553-557
79. Melera P.W., Davide J.P., and Oen H. Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines. J. Biol. Chem. 263 (1988) 1978-1990
80. Melera P.W., Hession C.A., Davide J.P., Scotto K.W., Biedler J.L., Meyers M.B., and Shanske S. Antifolate-resistant Chinese Hamster Cells. mRNA directed overproduction of multiple dihydrofolate reductases from a series of independently derived sublines containing amplified dihydrofolate reductase genes. J. Biol. Chem. 257 (1982) 12939-12949
81. Mendis K., Sina B.J., Marchesini P., and Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64 (2001) 97-106
82. Mennes M., Stiers P., Vandenbussche E., Vercruysse G., Uyttebroeck A., De Meyer G., and Van Cool S.W. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr. Blood Cancer 44 (2005) 478-486
83. Morris J.A., and McIvor R.S. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance. Biochem. Pharmacol. 47 (1994) 1207-1220
84. Nakano T., Spencer H.T., Appleman J.R., and Blakley R.L. Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis. Biochemistry 33 (1994) 9945-9952
85. Nzila A., Ochong E., Nduati E., Gilbert K., Winstanley P., Ward S., and Marsh K. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?. Trans. R. Soc. Trop. Med. Hyg. 99 (2005) 341-346
86. Oefner C., D'Arcy A., and Winkler F.K. Crystal structure of human dihydrofolate reductase complexed with folate. Eur. J. Biochem. 174 (1988) 377-385
87. Patel M., Sleep S.E., Lewis W.S., Spencer H.T., Mareya S.M., Sorrentino B.P., and Blakley R.L. Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Hum. Gene Ther. 8 (1997) 2069-2077
88. Persons D.A., Allay J.A., Bonifacino A., Lu T., Agricola B., Metzger M.E., Donahue R.E., Dunbar C.E., and Sorrentino B.P. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103 (2004) 796-803
89. Peterson D.S., Milhous W.K., and Wellems T.E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. U.S.A 87 (1990) 3018-3022
90. Peterson D.S., Walliker D., and Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 9114-9118
91. Pikis A., Donkersloot J.A., Rodriguez W.J., and Keith J.M. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. J. Infect. Dis. 178 (1998) 700-706
92. Prendergast N.J., Appleman J.R., Delcamp T.J., Blakley R.L., and Freisheim J.H. Effects of conversion of phenylalanine-31 to leucine on the function of human dihydrofolate reductase. Biochemistry 28 (1989) 4645-4650
93. Rothem L., Stark M., Kaufman Y., Mayo L., and Assaraf Y.G. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J. Biol. Chem. 279 (2004) 374-384
94. Sandefur C.I., Wooden J.M., Quaye I.K., Sirawaraporn W., and Sibley C.H. Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro. Mol. Biochem. Parasitol. 154 (2007) 1-5
95. Santos-Filho O.A., de Alencastro R.B., and Figueroa-Villar J.D. Homology modeling of wild type and pyrimethamine/cycloguanil-cross resistant mutant type Plasmodium falciparum dihydrofolate reductase. A model for antimalarial chemotherapy resistance. Biophys. Chem. 91 (2001) 305-317
96. Sauerbrey A., McPherson J.P., Zhao S.C., Banerjee D., and Bertino J.R. Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum. Gene Ther. 10 (1999) 2495-2504
97. Sawaya M.R., and Kraut J. Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence. Biochemistry 36 (1997) 586-603
98. Schweitzer B.I., Dicker A.P., and Bertino J.R. Dihydrofolate reductase as a therapeutic target. FASEB J. 4 (1990) 2441-2452
99. Schweitzer B.I., Srimatkandada S., Gritsman H., Sheridan R., Venkataraghavan R., and Bertino J.R. Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site-directed mutagenesis. J. Biol. Chem. 264 (1989) 20786-20795
100. Segel I.H. In Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (1993), John Wiley and sons
101. Simonsen C.C., and Levinson A.D. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 2495-2499
102. Sirawaraporn L.R., Chitnumsub P., Sirawaraporn W., Wooden J., Athapilly F., Turley S., and Hol H.W. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295 (2000) 307-323
103. Sirawaraporn W., Prapunwattana P., Sirawaraporn R., Yuthavong Y., and Santi D.V. The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression, and anti-folate-resistant mutants. J. Biol. Chem. 268 (1993) 21637-21644
104. Sirawaraporn W., Sathitkul T., Sirawaraporn R., Yuthavong Y., and Santi D.V. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 1124-1129
105. Sirawaraporn W., Sirawaraporn R., Cowman A.F., Yuthavong Y., and Santi D.V. Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry 29 (1990) 10779-10785
106. Sirawaraporn W., Yongkiettrakul S., Sirawaraporn R., Yuthavong Y., and Santi D.V. Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Exp. Parasitol. 87 (1997) 245-252
107. Slamon D.J., Romond E.H., and Perez E.A. Advances in adjuvant therapy for breast cancer. Clin. Adv. Hematol. Oncol. 4 (2006) 4-9
108. Sorrentino B.P. Clinical strategies for expansion of haematopoietic stem cells. Nat. Rev. Immunol. 4 (2004) 878-888
109. Spencer H.T., Sleep S.E., Rehg J.E., Blakley R.L., and Sorrentino B.P. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87 (1996) 2579-2587
110. Spencer H.T., Sorrentino B.P., Pui C.H., Chunduru S.K., Sleep S.E., and Blakley R.L. Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia 10 (1996) 439-446
111. Strojan P., Soba E., Budihna M., and Auersperg M. Radiochemotherapy with Vinblastine, Methotrexate, and Bleomycin in the treatment of verrucous carcinoma of the head and neck. J. Surg. Oncol. 92 (2005) 278-283
112. Tahar R., de Pecoulas P.E., Basco L.K., Chiadmi M., and Mazabraud A. Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Mol. Biochem. Parasitol. 113 (2001) 241-249
113. Takebe N., Xu L.C., MacKenzie K.L., Bertino J.R., and Moore M.A. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 9 (2002) 308-320
114. Takebe N., Zhao S.C., Adhikari D., Mineishi S., Sadelain M., Hilton J., Colvin M., Banerjee D., and Bertino J.R. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol. Ther. 3 (2001) 88-96
115. Tarnchompoo B., Sirichaiwat C., Phupong W., Intaraudom C., Sirawaraporn W., Kamchonwongpaisan S., Vanichtanankul J., Thebtaranonth Y., and Yuthavong Y. Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. J. Med. Chem. 45 (2002) 1244-1252
116. Thillet J., Absil J., Stone S.R., and Pictet R. Site-directed mutagenesis of mouse dihydrofolate reductase. Mutants with increased resistance to methotrexate and trimethoprim. J. Biol. Chem. 263 (1988) 12500-12508
117. Thillet J., and Pictet R. Transfection of DHFR- and DHFR+ mammalian cells using methotrexate-resistant mutants of mouse dihydrofolate reductase. FEBS Lett. 269 (1990) 450-453
118. Trippett T., Schlemmer S., Elisseyeff Y., Goker E., Wachter M., Steinherz P., Tan C., Berman E., Wright J.E., Rosowsky A., et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 80 (1992) 1158-1162
119. Volpato J.P., Fossati E., and Pelletier J.N. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase. J. Mol. Biol. 373 (2007) 599-611
120. Warlick C.A., Diers M.D., Wagner J.E., and McIvor R.S. In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J. Pharmacol. Exp. Ther. 300 (2002) 50-56
121. Watson M., Liu J.W., and Ollis D. Directed evolution of trimethoprim resistance in Escherichia coli. FEBS J. 274 (2007) 2661-2671
122. Young M.D., and Burgess R.W. Pyrimethamine resistance in Plasmodium vivax malaria. Bull. World Health Organ. 20 (1959) 27-36
123. Yuvaniyama J., Chitnumsub P., Kamchonwongpaisan S., Vanichtanankul J., Sirawaraporn W., Taylor P., Walkinshaw M.D., and Yuthavong Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 10 (2003) 357-365
124. Zhanel G.G., DeCorby M., Laing N., Weshnoweski B., Vashisht R., Tailor F., Nichol K.A., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagace-Wiens P., Walkty A., McCracken M., Mulvey M.R., Johnson J., and Hoban D.J. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob. Agents Chemother. 52 (2008) 1430-1437
125. Zhang K., and Rathod P.K. Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 296 (2002) 545-547
126. Zhao R., and Goldman I.D. Resistance to antifolates. Oncogene 22 (2003) 7431-7457
127. Zhao R., Titus S., Gao F., Moran R.G., and Goldman I.D. Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J. Biol. Chem. 275 (2000) 26599-26606
128. Zhao S.C., Banerjee D., Mineishi S., and Bertino J.R. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum. Gene Ther. 8 (1997) 903-909
129. Zolg J.W., Plitt J.R., Chen G.X., and Palmer S. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 36 (1989) 253-262